ArticleCommunications biology2021
Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report.
Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05017311 (Optimized Predictive Treatment In Medications for Unipolar Major Depression), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Who cites it
24 citing papers in PubMed.
- Towards causal inference-based antidepressant selection with brain and blood biomarkers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
- Effects of Blueberry Supplementation on Depression and Anxiety Symptoms in a Rural Louisiana Population.Nutrients · 2025Trial
- Assessing and refining a metabolite-based distress score for use in different populations within three US cohorts.medRxiv : the preprint server for health sciences · 2026Article
- The non-linear and linear effects of CYP2C19 metaboliser status on DNA methylation: a methylome-wide association study.Clinical epigenetics · 2026Article
- Sex-specific Serum Biomarker Associations with Antidepressant Treatment Outcomes in Depressive Disorders.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Article
- Gender Differences and Comorbidities in Major Depression.Advances in experimental medicine and biology · 2026Review
- Metabolomics biomarkers for precision psychiatry.Frontiers in psychiatry · 2026Review
- Compositional maturation of the microbiome and adaptive immunity in the postnatal period.Frontiers in immunology · 2026Article
- Discovery of molecular signature of long-term psychiatric sequelae in COVID-19 through proteome profiling of dried blood spots.Translational psychiatry · 2025Article
- Early Brain Functional Connectivity Changes Induced by Antidepressants and Placebo.bioRxiv : the preprint server for biology · 2025Article
- Longitudinal metabolic profiling of women using selective serotonin reuptake inhibitors during pregnancy.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Characterizing metabolomic and proteomic changes in depression: a systematic analysis.Molecular psychiatry · 2025Article
- The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.CNS neuroscience & therapeutics · 2025Article
- A network-based approach to discover diagnostic metabolite markers associated with depressive features for major depressive disorder.Frontiers in psychiatry · 2025Article
- The researcher's guide to selecting biomarkers in mental health studies.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Review
- Precision Medicine in Depression: The Role of Proteomics and Metabolomics in Personalized Treatment Approaches.Advances in experimental medicine and biology · 2024Review
- Assessing the Biological Mechanisms Linking Smoking Behavior and Cognitive Function: A Mediation Analysis of Untargeted Metabolomics.Metabolites · 2023Article
- Metabolomics and Self-Reported Depression, Anxiety, and Phobic Symptoms in the VA Normative Aging Study.Metabolites · 2023Article
- Metabolic Fingerprints of Effective Fluoxetine Treatment in the Prefrontal Cortex of Chronically Socially Isolated Rats: Marker Candidates and Predictive Metabolites.International journal of molecular sciences · 2023Article
- Predicting treatment outcome in depression: an introduction into current concepts and challenges.European archives of psychiatry and clinical neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
One of the biggest challenges in treating depression is the heterogeneous and qualitative nature of its clinical presentations. This highlights the need to find quantitative molecular markers to tailor existing treatment strategies to the individual's biological system. In this study, high-resolution metabolic phenotyping of urine and plasma samples from the CAN-BIND study collected before treatment with two common pharmacological strategies, escitalopram and aripiprazole, was performed. Here we show that a panel of LDL and HDL subfractions were negatively correlated with depression in males. For treatment response, lower baseline concentrations of apolipoprotein A1 and HDL were predictive of escitalopram response in males, while higher baseline concentrations of apolipoprotein A2, HDL and VLDL subfractions were predictive of aripiprazole response in females. These findings support the potential of metabolomics in precision medicine and the possibility of identifying personalized interventions for depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.